CD103+ cDC1s are critical for the generation of CD8+ T cell-mediated anti-tumor immunity, and their intratumoral abundance positively correlates with patient survival and predicts response to immunotherapy [6,12,13]. This evidence concerns the gene ITGAE and neoplasm.